Literature DB >> 12222837

Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: how useful are prognostic indices in routine clinical practice?

Fadime Akman1, Rachel A Cooper, Mehmet Sen, Yildiray Tanriver, Süleyman Kentli.   

Abstract

Although different prognostic indices for malignant gliomas have been developed, their validity outside of clinical trials has not been widely tested. The aim of this study was to determine whether the Medical Research Council (MRC) brain tumour prognostic index was able to stratify patients for survival managed in routine practice, and secondly to compare the results with our newly developed prognostic score which included tumour grade and only 3 prognostic groups. The MRC and the new prognostic index were calculated for a group of 119 adult patients with malignant glioma managed by surgical resection/biopsy and post-operative radiotherapy. For the MRC and new score, 6 and 3 prognostic groups were defined, respectively. For all patients median survival was 11 (2-66) months. The overall survival rate at 12 and 24 months were 43% and 18%, respectively. The MRC median and two-year survival rates were 14 months and 26% for a score of 1-10, 14 months and 27% for a score of 11-15, 13 months and 22% for a score of 16-20, 8 months and 10% for a score of 21-25, 8 months and 0% for those scoring 26-33. There was only one patient in the 34-38 group. For the new prognostic index, median and two-year survival rates were respectively 16 and 26%; 12 and 23%; 8 and 7% for the good, intermediate and poor prognostic groups. Both indices were significant factors for survival in univariate analysis (MRC index, p = 0.0089, new index p = 0.0002), but not in multivariate analysis. Both the MRC and our newly devised prognostic score were able to separate patients into good and poor prognostic groups, which may aid in treatment decisions, although there was less differentiation between the MRC groups especially over the first year. Both scores use routinely available factors. However, inclusion of tumour grade in the new score may be an advantage over the MRC index.

Entities:  

Mesh:

Year:  2002        PMID: 12222837     DOI: 10.1023/a:1016353614525

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma.

Authors:  K Anders; G G Grabenbauer; U Schuchardt; R Fahlbusch; R Fietkau; R Sauer; P Krauseneck
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

3.  Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression.

Authors:  A Perry; R B Jenkins; J R O'Fallon; P L Schaefer; D W Kimmel; M R Mahoney; B W Scheithauer; S M Smith; E M Hill; T J Sebo; R Levitt; J Krook; L K Tschetter; R F Morton; J C Buckner
Journal:  Cancer       Date:  1999-08-15       Impact factor: 6.860

4.  Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection.

Authors:  J Shinoda; N Sakai; S Murase; H Yano; T Matsuhisa; T Funakoshi
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

5.  A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.

Authors:  M D Groves; M H Maor; C Meyers; A P Kyritsis; K A Jaeckle; W K Yung; R E Sawaya; K Hess; J M Bruner; P Peterson; V A Levin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-08-01       Impact factor: 7.038

Review 6.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

7.  Misonidazole combined with hyperfractionation in the management of malignant glioma.

Authors:  D S Fulton; R C Urtasun; K H Shin; P H Geggie; H Thomas; P J Muller; J Moody; H Tanasichuk; B Mielke; E Johnson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Long-term survival in malignant glioma. Prognostic factors.

Authors:  S Phuphanich; S Ferrall; H Greenberg
Journal:  J Fla Med Assoc       Date:  1993-03

10.  A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. A report from the MRC Working Party on misonidazole in gliomas.

Authors: 
Journal:  Br J Radiol       Date:  1983-09       Impact factor: 3.039

View more
  5 in total

1.  Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes.

Authors:  Christopher L Mariani; Joshua G Kouri; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2006-04-13       Impact factor: 4.130

2.  Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo.

Authors:  Lindsay H Levkoff; Gregory P Marshall; Heather H Ross; Maria Caldeira; Brent A Reynolds; Meryem Cakiroglu; Christopher L Mariani; Wolfgang J Streit; Eric D Laywell
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

3.  Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas.

Authors:  Christopher L Mariani; Didier Rajon; Francis J Bova; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

4.  Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.

Authors:  Stephanie L Perry; Cindy Bohlin; David A Reardon; Annick Desjardins; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Journal:  J Neurooncol       Date:  2009-05-05       Impact factor: 4.130

5.  Symptom burden and surgical outcome in non-skull base meningiomas.

Authors:  Tobias Mederer; Sebastian Schachinger; Katharina Rosengarth; Anja Brosig; Karl-Michael Schebesch; Christian Doenitz; Nils-Ole Schmidt; Martin Andreas Proescholdt
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.